Rhythm Pharmaceuticals Valuation
| RYTM Stock | USD 96.06 2.41 2.45% |
At this time, the company appears to be undervalued. Rhythm Pharmaceuticals holds a recent Real Value of $114.01 per share. The prevailing price of the company is $96.06. Our model determines the value of Rhythm Pharmaceuticals from analyzing the company fundamentals such as Return On Equity of -0.86, shares outstanding of 66.74 M, and Operating Margin of (1.03) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Rhythm Pharmaceuticals' valuation include:
Price Book 44.1583 | Enterprise Value | Enterprise Value Ebitda (12.65) | Price Sales 37.6949 | Enterprise Value Revenue 36.1745 |
Undervalued
Today
Please note that Rhythm Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Rhythm Pharmaceuticals is based on 3 months time horizon. Increasing Rhythm Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Rhythm stock is determined by what a typical buyer is willing to pay for full or partial control of Rhythm Pharmaceuticals. Since Rhythm Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Rhythm Stock. However, Rhythm Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 96.06 | Real 114.01 | Target 141.57 | Hype 96.1 |
The intrinsic value of Rhythm Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Rhythm Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Rhythm Pharmaceuticals helps investors to forecast how Rhythm stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Rhythm Pharmaceuticals more accurately as focusing exclusively on Rhythm Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Rhythm Pharmaceuticals' intrinsic value based on its ongoing forecasts of Rhythm Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Rhythm Pharmaceuticals' closest peers.
Rhythm Pharmaceuticals Cash |
|
Rhythm Revenue by Product
Rhythm Pharmaceuticals Total Value Analysis
Rhythm Pharmaceuticals is at this time anticipated to have valuation of 6.31 B with market capitalization of 6.57 B, debt of 3.94 M, and cash on hands of 235.6 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Rhythm Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
6.31 B | 6.57 B | 3.94 M | 235.6 M |
Rhythm Pharmaceuticals Investor Information
About 99.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.75. Rhythm Pharmaceuticals recorded a loss per share of 3.1. The entity had not issued any dividends in recent years. Based on the key indicators related to Rhythm Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Rhythm Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Rhythm Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Rhythm Pharmaceuticals has an asset utilization ratio of 33.17 percent. This suggests that the Company is making $0.33 for each dollar of assets. An increasing asset utilization means that Rhythm Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Rhythm Pharmaceuticals Profitability Analysis
Based on Rhythm Pharmaceuticals' profitability indicators, Rhythm Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Rhythm Pharmaceuticals' ability to earn profits and add value for shareholders.Net Loss | First Reported 2013-12-31 | Previous Quarter -46.6 M | Current Value -52.9 M | Quarterly Volatility 26.5 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.7 | 0.81 |
|
|
For Rhythm Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Rhythm Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Rhythm Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Rhythm Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Rhythm Pharmaceuticals over time as well as its relative position and ranking within its peers.
Rhythm Pharmaceuticals Earnings per Share Projection vs Actual
The next projected EPS of Rhythm Pharmaceuticals is estimated to be -0.660425 with future projections ranging from a low of -0.9125 to a high of -0.2825. Rhythm Pharmaceuticals' most recent 12-month trailing earnings per share (EPS TTM) is at -3.1. Please be aware that the consensus of earnings estimates for Rhythm Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Rhythm Pharmaceuticals Earnings Estimation Breakdown
The calculation of Rhythm Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Rhythm Pharmaceuticals is estimated to be -0.660425 with the future projection ranging from a low of -0.9125 to a high of -0.2825. Please be aware that this consensus of annual earnings estimates for Rhythm Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.91 Lowest | Expected EPS | -0.28 Highest |
Rhythm Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Rhythm Pharmaceuticals' value are higher than the current market price of the Rhythm Pharmaceuticals stock. In this case, investors may conclude that Rhythm Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Rhythm Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 15 | 75.17% | 0.0 | -0.660425 | -3.1 |
Rhythm Pharmaceuticals Ownership Allocation
The majority of Rhythm Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Rhythm Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Rhythm Pharmaceuticals. Please pay attention to any change in the institutional holdings of Rhythm Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.Rhythm Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 130.13 M. Net Loss for the year was (260.6 M) with profit before overhead, payroll, taxes, and interest of 155.86 M.About Rhythm Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Rhythm Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Rhythm Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Rhythm Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Rhythm Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Rhythm Pharmaceuticals. We calculate exposure to Rhythm Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Rhythm Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 134.3 M | 141 M | |
| Pretax Profit Margin | (1.80) | (1.89) | |
| Operating Profit Margin | (1.84) | (1.93) | |
| Net Loss | (1.80) | (1.89) | |
| Gross Profit Margin | 0.81 | 0.70 |
Rhythm Pharmaceuticals Current Valuation Indicators
Rhythm Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Rhythm Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Rhythm Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Rhythm Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Rhythm Pharmaceuticals' worth.When determining whether Rhythm Pharmaceuticals is a strong investment it is important to analyze Rhythm Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rhythm Pharmaceuticals' future performance. For an informed investment choice regarding Rhythm Stock, refer to the following important reports: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Will Biotechnology sector continue expanding? Could Rhythm diversify its offerings? Factors like these will boost the valuation of Rhythm Pharmaceuticals. Anticipated expansion of Rhythm directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Rhythm Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.10) | Revenue Per Share | Quarterly Revenue Growth 0.543 | Return On Assets | Return On Equity |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Rhythm Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rhythm Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Rhythm Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.